Top

02-09-2016 | Genitourinary cancers | Book chapter | Article

9. Epidemiology of Prostate Cancer

Authors: Lorelei A. Mucci, Kathryn M. Wilson, Edward L. Giovannucci

Publisher: Springer International Publishing

Abstract

Prostate cancer is a major cause of disease and mortality among men, particularly in Western countries. In this chapter, we discuss the evidence surrounding specific lifestyle and dietary factors in the prevention of prostate cancer, with a focus on prevention of lethal disease. We provide global descriptive data around prostate cancer incidence and mortality, and summarize evidence for the following selected risk factors: genetics, obesity and weight change, physical activity, smoking, antioxidant intake, vitamin D and calcium, and statins.

Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366–81.PubMedCrossRef

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.PubMedCrossRef

Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42.PubMedPubMedCentralCrossRef

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–55.PubMedPubMedCentralCrossRef

Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 2015;107(7).

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.PubMedPubMedCentralCrossRef

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St. Gallen advanced prostate cancer consensus conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604.PubMedPubMedCentralCrossRef

Ferlay J, Bray F, Pisani P, Parkin MX. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press. Report No. 2004.

GLOBOCAN 2008 cancer fact sheet: prostate cancer incidence and mortality worldwide in 2008 summary [Internet]. 2008. Available from http://globocan.iarc.fr/factsheets/cancers/prostate.asp. Cited 16 Nov 2011.

10.

SEER cancer statistics review 1975–2008. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site [Internet]. 2011.

11.

Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63(6):963–6.PubMedPubMedCentralCrossRef

12.

Yu H, Harris RE, Gao YT, Gao R, Wynder EL. Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol. 1991;20(1):76–81.PubMedCrossRef

13.

Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.PubMedCrossRef

14.

Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008;28(3):323–31.PubMedCrossRef

15.

Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994). Eur J Cancer. 2005;41(3):411–5.PubMedCrossRef

16.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981–90.PubMedCrossRef

17.

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571–8.PubMedPubMedCentralCrossRef

18.

Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97(6):1507–16.PubMedCrossRef

19.

Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–101.PubMedCrossRef

20.

Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713–9.PubMedCrossRef

21.

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385–91, 91e1–2.

22.

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(10):1103–9.PubMedPubMedCentralCrossRef

23.

MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989–1003.PubMedCrossRef

24.

Taksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer. 2012;118(17):4280–9.PubMedCrossRef

25.

Hemminki K, Czene K. Attributable risks of familial cancer from the family-cancer database. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1638–44.PubMed

26.

Brandt A, Sundquist J, Hemminki K. Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Ann Oncol. 2011;23:251–6.PubMedCrossRef

27.

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85.PubMedCrossRef

28.

Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The heritability of prostate cancer in the nordic twin study of cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2303–10.PubMedPubMedCentralCrossRef

29.

Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310–5.PubMedCrossRef

30.

Hoffmann TJ, Van Den Eeden SK, Sakoda LC, Jorgenson E, Habel LA, Graff RE, et al. A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. Cancer Discov. 2015;5(8):878–91.PubMedPubMedCentralCrossRef

31.

Pomerantz MM, Freedman ML. Genetics of prostate cancer risk. Mt Sinai J Med. 2010;77(6):643–54.PubMedCrossRef

32.

Shui IM, Lindstrom S, Kibel AS, Berndt SI, Campa D, Gerke T, et al. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014;65(6):1069–75.PubMedPubMedCentralCrossRef

33.

Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet. 2011;7(5):e1001387.PubMedPubMedCentralCrossRef

34.

Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67.PubMedPubMedCentralCrossRef

35.

Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.PubMedCrossRef

36.

Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–47.PubMedPubMedCentralCrossRef

37.

Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56(1):34–43.PubMedCrossRef

38.

Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol. 2004;92(4):237–53.PubMedCrossRef

39.

De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256–69.PubMedPubMedCentralCrossRef

40.

Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer. 2011;105(7):1061–8.PubMedPubMedCentralCrossRef

41.

Robinson WR, Poole C, Godley PA. Systematic review of prostate cancer’s association with body size in childhood and young adulthood. Cancer Causes Control. 2008;19(8):793–803.PubMedCrossRef

42.

Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486–501.CrossRef

43.

Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2014;23(5):890–2.PubMedCrossRef

44.

Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3252–61.PubMedCrossRef

45.

MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1417–21.PubMed

46.

Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(8):557–63.PubMed

47.

Nomura A, Heilbrun LK, Stemmermann GN. Body mass index as a predictor of cancer in men. J Natl Cancer Inst. 1985;74(2):319–23.PubMed

48.

Cerhan JR, Torner JC, Lynch CF, Rubenstein LM, Lemke JH, Cohen MB, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ rural health study (United States). Cancer Causes Control. 1997;8(2):229–38.PubMedCrossRef

49.

Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000;10(6):361–9.PubMedCrossRef

50.

Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Netherlands cohort study. Am J Epidemiol. 2000;151(6):541–9.PubMedCrossRef

51.

Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, et al. Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer. 2000;89(3):259–64.PubMedCrossRef

52.

Jonsson F, Wolk A, Pedersen NL, Lichtenstein P, Terry P, Ahlbom A, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry. Int J Cancer. 2003;106(4):594–9.PubMedCrossRef

53.

Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-control study of anthropometric measures and prostate cancer risk. Int J Cancer. 2004;110(2):278–83.PubMedCrossRef

54.

Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol. 2007;165(11):1271–9.PubMedCrossRef

55.

Hernandez BY, Park SY, Wilkens LR, Henderson BE, Kolonel LN. Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2413–21.PubMedPubMedCentralCrossRef

56.

Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila). 2011;4(4):544–51.CrossRef

57.

Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med. 2005;165(9):1005–10.PubMedCrossRef

58.

Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev. 2005;14(1):275–9.PubMed

59.

Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29(6):726–32.PubMedPubMedCentralCrossRef

60.

Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011;71(11):3889–95.PubMedPubMedCentralCrossRef

61.

US Department of Health and Human Services. The health consequences of smoking. A report of the surgeon general. Washington, DC: US Dept of Health and Human Services. 2004.

62.

Giovannucci E, Rimm EB, Ascherio A, Colditz GA, Spiegelman D, Stampfer MJ, et al. Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev. 1999;8(4 Pt 1):277–82.PubMed

63.

Byrne MM, Davila EP, Zhao W, Parker D, Hooper MW, Caban-Martinez A, et al. Cancer screening behaviors among smokers and non-smokers. Cancer Epidemiol. 2010;34(5):611–7.PubMedCrossRef

64.

Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol. 2004;171(4):1543–6.PubMedCrossRef

65.

Moreira DM, Antonelli JA, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, et al. Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2010;76(5):1218–23.PubMedPubMedCentralCrossRef

66.

Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011;103(10):835–8.PubMedPubMedCentralCrossRef

67.

Pantarotto J, Malone S, Dahrouge S, Gallant V, Eapen L. Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy. BJU Int. 2007;99(3):564–9.PubMedCrossRef

68.

Oefelein MG, Resnick MI. Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol. 2004;171(6 Pt 1):2281–4.PubMedCrossRef

69.

Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305(24):2548–55.PubMedPubMedCentralCrossRef

70.

Meydani M, Vitamin E. Lancet. 1995;345(8943):170–5.PubMedCrossRef

71.

Meydani SN, Hayek MG. Vitamin E and aging immune response. Clin Geriatr Med. 1995;11(4):567–76.PubMed

72.

Gunawardena K, Murray DK, Meikle AW. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate. 2000;44(4):287–95.PubMedCrossRef

73.

Ripoll EA, Rama BN, Webber MM. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J Urol. 1986;136(2):529–31.PubMed

74.

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The alpha-tocopherol, beta carotene cancer prevention study group. N Engl J Med. 1994;330(15):1029–35.

75.

Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90(6):440–6.PubMedCrossRef

76.

Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85(18):1483–92.PubMedCrossRef

77.

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and Vitamin E cancer prevention trial (SELECT). JAMA. 2009;301(1):39–51.PubMedCrossRef

78.

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the selenium and Vitamin E cancer prevention trial (SELECT). JAMA. 2011;306(14):1549–56.PubMedPubMedCentralCrossRef

79.

Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the physicians’ health study II randomized controlled trial. JAMA. 2009;301(1):52–62.PubMedCrossRef

80.

Peters U, Littman AJ, Kristal AR, Patterson RE, Potter JD, White E. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. Cancer Causes Control. 2008;19(1):75–87.PubMedCrossRef

81.

Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer. 1996;66(2):145–50.PubMedCrossRef

82.

Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006;98(4):245–54.PubMedCrossRef

83.

Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8(10):893–9.PubMed

84.

Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999;59(6):1225–30.PubMed

85.

Combs GF Jr, Combs SB. The nutritional biochemistry of selenium. Annu Rev Nutr. 1984;4:257–80.PubMedCrossRef

86.

Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev. 2000;9(11):1171–82.PubMed

87.

Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 1998;125(1–2):103–10.PubMedCrossRef

88.

Rayman MP. The importance of selenium to human health. Lancet. 2000;356(9225):233–41.PubMedCrossRef

89.

Neve J. Human selenium supplementation as assessed by changes in blood selenium concentration and glutathione peroxidase activity. J Trace Elem Med Biol. 1995;9(2):65–73.PubMedCrossRef

90.

Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial. BJU Int. 2003;91(7):608–12.PubMedCrossRef

91.

Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA. 1996;276(24):1957–63.PubMedCrossRef

92.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456.PubMedPubMedCentralCrossRef

93.

Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst. 2004;96(9):696–703.PubMedCrossRef

94.

Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998;90(16):1219–24.PubMedCrossRef

95.

Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001;166(6):2034–8.PubMedCrossRef

96.

Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92(24):2018–23.PubMedCrossRef

97.

Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(9):883–7.PubMed

98.

van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12(9):866–71.PubMed

99.

Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10(10):1069–76.PubMed

100.

Hartman TJ, Albanes D, Pietinen P, Hartman AM, Rautalahti M, Tangrea JA, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 1998;7(4):335–40.PubMed

101.

Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 2008;52(11):1261–72.PubMedPubMedCentralCrossRef

102.

Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol. 2011;29(17):2386–90.PubMedCrossRef

103.

Marshall JR, Tangen CM, Sakr WA, Wood DP Jr, Berry DL, Klein EA, et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila). 2011;4(11):1761–9.PubMedPubMedCentralCrossRef

104.

Ilic D, Forbes KM, Hassed C. Lycopene for the prevention of prostate cancer. Cochrane Database System Rev. 2011;11:CD008007.

105.

Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87(23):1767–76.PubMedCrossRef

106.

Cerhan JR, Cantor KP, Williamson K, Lynch CF, Torner JC, Burmeister LF. Cancer mortality among Iowa farmers: recent results, time trends, and lifestyle factors (United States). Cancer Causes Control. 1998;9(3):311–9.PubMedCrossRef

107.

Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in adventist men. Cancer. 1989;64(3):598–604.PubMedCrossRef

108.

Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(1):92–8.PubMedCrossRef

109.

Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, et al. Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol. 2010;172(5):566–77.PubMedPubMedCentralCrossRef

110.

Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst. 2002;94(5):391–8.PubMedCrossRef

111.

Le Marchand L, Hankin JH, Kolonel LN, Wilkens LR. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. Am J Epidemiol. 1991;133(3):215–9.PubMed

112.

Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer. 1997;76(5):678–87.PubMedPubMedCentralCrossRef

113.

Meyer F, Bairati I, Fradet Y, Moore L. Dietary energy and nutrients in relation to preclinical prostate cancer. Nutr Cancer. 1997;29(2):120–6.PubMedCrossRef

114.

Deneo-Pellegrini H, De Stefani E, Ronco A, Mendilaharsu M. Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer. 1999;80(3–4):591–7.PubMedPubMedCentralCrossRef

115.

Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer. 1999;34(2):173–84.PubMedCrossRef

116.

Vogt TM, Mayne ST, Graubard BI, Swanson CA, Sowell AL, Schoenberg JB, et al. Serum lycopene, other serum carotenoids, and risk of prostate cancer in US blacks and whites. Am J Epidemiol. 2002;155(11):1023–32.PubMedCrossRef

117.

Bosetti C, Talamini R, Montella M, Negri E, Conti E, Franceschi S, et al. Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy. Int J Cancer. 2004;112(4):689–92.PubMedCrossRef

118.

Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European prospective investigation into cancer and nutrition study. Am J Clin Nutr. 2007;86(3):672–81.PubMed

119.

Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H, et al. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pacific J Cancer Prev (APJCP). 2007;8(3):422–8.

120.

Kristal AR, Till C, Platz EA, Song X, King IB, Neuhouser ML, et al. Serum lycopene concentration and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2011;20(4):638–46.PubMedPubMedCentralCrossRef

121.

Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Vegetable and fruit consumption and prostate cancer risk: a cohort study in The Netherlands. Cancer Epidemiol Biomarkers Prev. 1998;7(8):673–80.PubMed

122.

Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, et al. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007;16(5):962–8.PubMedCrossRef

123.

Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW. Serum levels of folate, lycopene, beta-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr. 2010;64(10):1235–8.PubMedCrossRef

124.

Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol. 2003;157(4):335–44.PubMedCrossRef

125.

Jian L, Lee AH, Binns CW. Tea and lycopene protect against prostate cancer. Asia Pacific J Clin Nutr. 2007;16(Suppl 1):453–7.

126.

Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev. 2004;13(3):340–5.PubMed

127.

Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13(2):260–9.PubMedCrossRef

128.

Jian L, Du CJ, Lee AH, Binns CW. Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer. 2005;113(6):1010–4.PubMedCrossRef

129.

Karppi J, Kurl S, Nurmi T, Rissanen TH, Pukkala E, Nyyssonen K. Serum lycopene and the risk of cancer: the Kuopio ischaemic heart disease risk factor (KIHD) study. Ann Epidemiol. 2009;19(7):512–8.PubMedCrossRef

130.

Maiani G, Caston MJ, Catasta G, Toti E, Cambrodon IG, Bysted A, et al. Carotenoids: actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans. Mol Nutr Food Res. 2009;53(Suppl 2):S194–218.PubMedCrossRef

131.

Giovannucci E. Commentary: serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Causes Control. 2011;22(7):1055–9.PubMedCrossRef

132.

Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. 2005;97(23):1768–77.PubMedCrossRef

133.

Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjonneland A, et al. Animal foods, protein, calcium and prostate cancer risk: the European prospective investigation into cancer and nutrition. Br J Cancer. 2008;98(9):1574–81.PubMedPubMedCentralCrossRef

134.

Mitrou PN, Albanes D, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, et al. A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Int J Cancer. 2007;120(11):2466–73.PubMedCrossRef

135.

Park Y, Mitrou PN, Kipnis V, Hollenbeck A, Schatzkin A, Leitzmann MF. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP diet and health study. Am J Epidemiol. 2007;166(11):1270–9.PubMedCrossRef

136.

Kesse E, Bertrais S, Astorg P, Jaouen A, Arnault N, Galan P, et al. Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplementation en Vitamines et Mineraux Antioxydants) study. Br J Nutr. 2006;95(3):539–45.PubMedCrossRef

137.

Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS. Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. Cancer Epidemiol Biomarkers Prev. 2008;17(4):930–7.PubMedCrossRef

138.

Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2623–30.PubMedCrossRef

139.

Rohrmann S, Platz EA, Kavanaugh CJ, Thuita L, Hoffman SC, Helzlsouer KJ. Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. Cancer Causes Control. 2007;18(1):41–50.PubMedCrossRef

140.

Butler LM, Wong AS, Koh WP, Wang R, Yuan JM, Yu MC. Calcium intake increases risk of prostate cancer among Singapore Chinese. Cancer Res. 2010;70(12):4941–8.PubMedPubMedCentralCrossRef

141.

Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):203–10.PubMedCrossRef

142.

Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National health and nutrition examination epidemiologic follow-up study cohort. Am J Clin Nutr. 2005;81(5):1147–54.PubMed

143.

Skinner HG, Schwartz GG. Serum calcium and incident and fatal prostate cancer in the National health and nutrition examination survey. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2302–5.PubMedPubMedCentralCrossRef

144.

Skinner HG, Schwartz GG. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(2):575–8.PubMedPubMedCentralCrossRef

145.

Halthur C, Johansson AL, Almquist M, Malm J, Gronberg H, Manjer J, et al. Serum calcium and the risk of prostate cancer. Cancer Causes Control. 2009;20(7):1205–14.PubMedCrossRef

146.

Van Hemelrijck M, Hermans R, Michaelsson K, Melvin J, Garmo H, Hammar N, et al. Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2012;23(8):1349–58.PubMedCrossRef

147.

Park Y, Leitzmann MF, Subar AF, Hollenbeck A, Schatzkin A. Dairy food, calcium, and risk of cancer in the NIH-AARP diet and health study. Arch Intern Med. 2009;169(4):391–401.PubMedPubMedCentralCrossRef

148.

Koh KA, Sesso HD, Paffenbarger RS Jr, Lee IM. Dairy products, calcium and prostate cancer risk. Br J Cancer. 2006;95(11):1582–5.PubMedPubMedCentralCrossRef

149.

Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67(3):253–6.PubMedCrossRef

150.

Ali MM, Vaidya V. Vitamin D and cancer. J Cancer Res Ther. 2007;3(4):225–30.PubMedCrossRef

151.

Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev. 2003;12(2):84–9.PubMed

152.

Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002;94(14):1099–106.PubMedCrossRef

153.

Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control. 1998;9(6):567–82.PubMedCrossRef

154.

Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control. 1998;9(6):559–66.PubMedCrossRef

155.

Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D, et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control. 2000;11(9):859–67.PubMedCrossRef

156.

Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(8):719–25.PubMed

157.

Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2(5):467–72.PubMed

158.

Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control. 1995;6(3):235–9.PubMedCrossRef

159.

Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(2):121–6.PubMed

160.

Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control. 1998;9(4):425–32.PubMedCrossRef

161.

Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004;15(3):255–65.PubMedCrossRef

162.

Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol. 2004;89–90(1–5):533–7.PubMedCrossRef

163.

Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European prospective investigation into cancer and nutrition (EPIC). Am J Epidemiol. 2009;169(10):1223–32.PubMedPubMedCentralCrossRef

164.

Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4(3):e103.PubMedPubMedCentralCrossRef

165.

Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010;21(8):1297–303.PubMedPubMedCentralCrossRef

166.

Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2784–6.PubMedCrossRef

167.

Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer. 2010;46(5):932–6.PubMedPubMedCentralCrossRef

168.

Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131(5):1187–96.PubMedCrossRef

169.

Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100(11):796–804.PubMedPubMedCentralCrossRef

170.

Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1850–60.PubMedPubMedCentralCrossRef

171.

Meyer HE, Robsahm TE, Bjorge T, Brustad M, Blomhoff R. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr. 2013;97(1):147–54.PubMedCrossRef

172.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the selenium and Vitamin E cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1494–504.PubMedPubMedCentralCrossRef

173.

Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010;70(13):1448–60.PubMedPubMedCentralCrossRef

174.

Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011;29(17):2378–85.PubMedPubMedCentralCrossRef

175.

Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS ONE. 2011;6(4):e18625.PubMedPubMedCentralCrossRef

176.

Lu Y, Zhai L, Zeng J, Peng Q, Wang J, Deng Y, et al. Coffee consumption and prostate cancer risk: an updated meta-analysis. Cancer Causes Control. 2014;25(5):591–604.PubMedCrossRef

177.

Cao S, Liu L, Yin X, Wang Y, Liu J, Lu Z. Coffee consumption and risk of prostate cancer: a meta-analysis of prospective cohort studies. Carcinogenesis. 2014;35(2):256–61.PubMedCrossRef

178.

Zhong S, Chen W, Yu X, Chen Z, Hu Q, Zhao J. Coffee consumption and risk of prostate cancer: an up-to-date meta-analysis. Eur J Clin Nutr. 2014;68(3):330–7.PubMedCrossRef

179.

Discacciati A, Orsini N, Wolk A. Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer—a dose-response meta-analysis. Ann Oncol. 2014;25(3):584–91.PubMedCrossRef

180.

Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98(24):1819–25.PubMedCrossRef

181.

Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE. 2012;7(10):e46691.PubMedPubMedCentralCrossRef

182.

Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate. 2013;73(11):1214–22.PubMedPubMedCentralCrossRef

183.

Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. The New Engl J Med. 2012;367(19):1792–802.PubMedCrossRef

184.

Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol Official J Am Soc Clin Oncol. 2013;31(25):3069–75.CrossRef

185.

Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2013.

186.

Yu O EM, Benayoun S, Aprikian A, Baptist G, Suissa S, Azoulay L. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2013;31(27).

» This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Medicine Matters Oncology

Abstract